NASDAQ:HBIO Harvard Bioscience (HBIO) Stock Price, News & Analysis $8.55 +0.13 (+1.52%) As of 11:23 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Harvard Bioscience Stock (NASDAQ:HBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harvard Bioscience alerts:Sign Up Key Stats Today's Range$8.49▼$8.5250-Day Range$7.08▼$8.5652-Week Range$4.00▼$9.40Volume885 shsAverage Volume33,050 shsMarket Capitalization$38.91 millionP/E RatioN/ADividend YieldN/APrice Target$6.75Consensus RatingHold Company Overview Harvard Bioscience, Inc. (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies. The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables. Its products are marketed under several brands, including Harvard Apparatus, BTX, DSI and ScienCell, serving academic institutions, pharmaceutical and biotechnology companies, hospitals and other research organizations. Founded in 1901, Harvard Bioscience serves customers in North America and international markets through direct sales, distributors and digital channels. The company’s operations are focused on providing specialized research tools that help scientists conduct experiments, analyze biological processes and develop new therapies.AI Generated. May Contain Errors. Read More Harvard Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreHBIO MarketRank™: 0.90205187766 of 5 starsHarvard Bioscience scored higher than 18% of companies evaluated by MarketBeat, and ranked 820th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingHarvard Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Downside RiskHarvard Bioscience has a consensus price target of $6.75, representing about 20.2% downside from its current price of $8.46.Amount of Analyst CoverageHarvard Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Harvard Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Harvard Bioscience is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harvard Bioscience is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarvard Bioscience has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Harvard Bioscience's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.33% of the float of Harvard Bioscience has been sold short.Short Interest Ratio / Days to CoverHarvard Bioscience has a short interest ratio ("days to cover") of 3.15, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Harvard Bioscience has recently increased by 11.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarvard Bioscience does not currently pay a dividend.Dividend GrowthHarvard Bioscience does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.91 News SentimentHarvard Bioscience has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Harvard Bioscience this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for HBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Harvard Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders17.03% of the stock of Harvard Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harvard Bioscience's insider trading history. Receive HBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBIO Stock News HeadlinesHarvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ETOctober 27 at 7:30 AM | globenewswire.comHarvard Bioscience Announces Creation of Scientific Advisory BoardOctober 6, 2026 | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 29 at 1:00 AM | Porter & Company (Ad)Harvard Bioscience (HBIO) Q2 2026 Earnings Call TranscriptAugust 18, 2026 | finance.yahoo.comHarvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ...August 12, 2026 | finance.yahoo.comHarvard Bioscience Announces Second Quarter 2026 Financial ResultsAugust 12, 2026 | markets.businessinsider.comHarvard Bioscience, Inc. (HBIO) Q2 FY2026 earnings call transcriptAugust 12, 2026 | finance.yahoo.comHarvard Bioscience targets 3% to 5% full-year 2026 revenue growth as CMT and China mix shifts gross margin to 57% to 59%August 12, 2026 | seekingalpha.comSee More Headlines HBIO Stock Analysis - Frequently Asked Questions How have HBIO shares performed this year? Harvard Bioscience's stock was trading at $6.6880 on January 1st, 2026. Since then, HBIO shares have increased by 26.4% and is now trading at $8.4550. How were Harvard Bioscience's earnings last quarter? Harvard Bioscience, Inc. (NASDAQ:HBIO) issued its quarterly earnings data on Tuesday, August, 11th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.07. The medical instruments supplier earned $22.73 million during the quarter, compared to analysts' expectations of $21.45 million. Harvard Bioscience had a negative net margin of 11.86% and a negative trailing twelve-month return on equity of 33.13%. Read the conference call transcript. When did Harvard Bioscience's stock split? Harvard Bioscience's stock reverse split before market open on Monday, March 16th 2026.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, March 15th 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Does Harvard Bioscience have any subsidiaries? Harvard Bioscience subsidiaries include Data Sciences International. How do I buy shares of Harvard Bioscience? Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harvard Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harvard Bioscience investors own include NVIDIA (NVDA), Qualcomm (QCOM), Intel (INTC), GE Aerospace (GE), Nokia (NOK), Sorrento Therapeutics (SRNE) and Tilray Brands (TLRY). Company Calendar Last Earnings8/11/2026Today10/29/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 HBIO's financial health is in the Green zone, according to TradeSmith. HBIO has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:HBIO CIK1123494 Webwww.harvardbioscience.com Phone(508) 893-8999Fax508-429-5732Employees339Year Founded1901Price Target and Rating Average Price Target for Harvard Bioscience$6.75 High Price Target$7.50 Low Price Target$6.00 Potential Upside/Downside-20.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.70 million Net Margins-11.86% Pretax Margin-12.01% Return on Equity-33.13% Return on Assets-4.80% Debt Debt-to-Equity Ratio4.94 Current Ratio1.87 Quick Ratio0.98 Sales & Book Value Annual Sales$87.81 million Price / Sales0.44 Cash Flow$12.14 per share Price / Cash Flow0.70 Book Value$3.07 per share Price / Book2.77Miscellaneous Outstanding Shares4,552,000Free Float3,777,000Market Cap$38.67 million OptionableNo Data Beta1.50 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:HBIO) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harvard Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harvard Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
